VANCOUVER, BC — Bold Therapeutics, a clinical-stage biopharmaceutical company developing first-in-class oncology therapeutics, announced positive interim results from a Phase 2 clinical trial evaluating BOLD-100 in combination with standard-of-care chemotherapy… Read More
New treatment option for Canadians living with rare and serious X-chromosome linked congenital bleeding disorder MISSISSAUGA, ON — /CNW/ — Health Canada has approved Alhemo™, the first anti-tissue factor pathway inhibitor… Read More
VANCOUVER, BC — (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a clinical stage pharmaceutical development company, is pleased to announce that… Read More
In-depth characterization of CD3-binding antibodies reveals molecules with binding and functional properties that are differentiated from antibodies commonly used for T-cell engager development Discovery of antibodies with high specificity for… Read More
Indications under review include prevention of RSV in infants from birth through 6 months of age by immunization of pregnant individuals, and in individuals 60 years of age and older…. Read More
